Thank you for attending the Optometric Glaucoma Symposium 2024

The evaluation for credit and certificates will be available at the conclusion of the meeting

Thank you for attending Optometric Glaucoma Symposium 2024.

The evaluation for credit and certificates will be available at the conclusion of the meeting.

Scroll back to top

Details

Overview
The 9^th Annual Optometric Glaucoma Symposium is a CE meeting dedicated specifically to providing the newest information in glaucoma management and treatment. Now in its 9^th year, this meeting will bring together a group of experts in glaucoma and ocular health to raise physician awareness to key developments and current issues in glaucoma. Attendees will be updated on recent study findings, glaucoma management algorithms, effects of comorbidities on the management of glaucoma, and learn to interpret data collected in management of glaucoma. By keeping abreast of the latest study findings, treatments, and technologies, optometrists will be better prepared to provide timely diagnoses and employ optimal treatment and management strategies for their patients.
Supported by unrestricted educational grants from Alcon and Sight Sciences.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Through case-based studies, identify normal tension glaucoma
- Discuss the benefits of home tonometry
- Identify the connections between the eye, gut and brain
- Discuss the latest options for when and how to implement the latest IOL’s
- Discuss glaucoma challenges, opportunities, and future management in 2024
Accreditation
Evolve is an accredited COPE administrator.
This activity, COPE Activity Number 125388, is accredited by COPE for continuing education for optometrists. This course is approved for 3 hours of CE.
Course # 82778-GL
Activity # 125388
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Faculty and Disclosures
Andrew G. Iwach, MD
Associate Clinical Professor
University of California, San Francisco
San Francisco, California

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Andrew G. Iwach, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Belkin Lasers, and OMIC. Shareholder: Eyenovia
John G. Flanagan, PhD, DSc, FCOptom, FAAO, FARVO has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Carl Zeiss Meditec and Topcon Healthcare. Advisor: Zilia. Shareholder: InjectSense and Thornhill Medical.
L. Jay Katz, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Glaukos. Speakers Bureau: Allergan, Shareholder: Glaukos, Mati Pharma, and Olleyes.
Malini V. Pasricha, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant and Speaker’s Bureau: Genentech.
Michael Chaglasian, OD, FAAO has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Topcon Healthcare. Grant/Research Support: Optos, Topcon Healthcare. Speaker’s Bureau: Bausch + Lomb.
Robert L. Stamper, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant and Shareholder: Inject Sense
Ruth D. Williams, MD has had no financial relationships or affiliations with ineligible companies.
Shan Lin, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Iridex Corporation, Bausch + Lomb, Dompe, ArcScan, and Santen Pharmaceuticals. Speakers Bureau: Iridex Corporation.
Sunita Radhakrishnan, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Netra Systems
Terri Pickering, MD has had no financial relationships or affiliations with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, the Glaucoma Research and Education Group, Alcon or Sight Sciences.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 04/30/2024

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Deepak Sambhara, MD
0.25 credits
- Deepak Sambhara, MD
0.25 credits
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Esther Lee Kim, MD
0.25 credits
- Esther Lee Kim, MD
0.25 credits
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
David Eichenbaum, MD
0.25 credits
- David Eichenbaum, MD
0.25 credits

Thank you for attending the Optometric Glaucoma Symposium 2024

The evaluation for credit and certificates will be available at the conclusion of the meeting

Thank you for attending Optometric Glaucoma Symposium 2024.

The evaluation for credit and certificates will be available at the conclusion of the meeting.

Recommended

Title